Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signatures.
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.
